Medication-Related Osteonecrosis of the Jaw: Basic and Translational Science Updates

Matthew R Allen

doi:10.1016/j.coms.2015.06.002

Medication-Related Osteonecrosis of the Jaw: Basic and Translational Science Updates

Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):497-508. doi: 10.1016/j.coms.2015.06.002. Epub 2015 Aug 13.

Author

Matthew R Allen¹

Affiliation

¹ Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Drive, MS-5035, Indianapolis, IN 46202, USA. Electronic address: matallen@iupui.edu.

PMID: 26277349
DOI: 10.1016/j.coms.2015.06.002

Abstract

In the late 1990s and the early 2000s, bisphosphonates had become the clinical pillar of excellence for treating metabolic bone disease, and thus their connection with osteonecrosis of the jaw (ONJ) caused significant concern. Over the past decade, progress has been made in understanding what is now referred to as medication-related ONJ (MRONJ), because of its connections to agents other than bisphosphonates, although in many respects the progress has been slow. This review highlights the key basic science and translational (animal) studies in the area of MRONJ and suggests areas of focus as the field moves into the next decade.

Keywords: Antiremodeling agents; Bisphosphonates; Denosumab; ONJ.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / toxicity*
Animals
Bisphosphonate-Associated Osteonecrosis of the Jaw / pathology
Bone Density Conservation Agents / toxicity*
Diphosphonates / toxicity*
Humans
Jaw Diseases / chemically induced*
Jaw Diseases / pathology
Osteonecrosis / chemically induced*
Osteonecrosis / pathology
Translational Research, Biomedical

Substances

Angiogenesis Inhibitors
Bone Density Conservation Agents
Diphosphonates